GlobeNewswire by notified

Concurrent Stockholders Approve Proposal to Sell Content Delivery & Storage Business to Vecima Networks

Share

ATLANTA , December 13, 2017 - The stockholders of Concurrent (NASDAQ:CCUR), a global leader in storage, protection, transformation, and delivery of visual media assets, have approved all proposals presented at a special meeting of its stockholders held on December 13, 2017.  The proposals related to the sale of Concurrent's content delivery and storage business to Vecima Networks Inc. (TSX:VCM). 

Derek Elder, President and CEO of Concurrent, commented, "The Board of Directors and our management team appreciate the overwhelming support of our proposals from Concurrent's stockholders.  We expect to close the announced transaction with Vecima Networks by the end of the calendar year.  The investment committee established by the Board of Directors will continue to evaluate options to maximize the value of the Company's remaining assets after the close of the sale to Vecima."

The specific voting results for each of the proposals considered at the special stockholder's meeting are provided in Form 8-K filed by Concurrent on December 13, 2017.

About Concurrent

Concurrent (NASDAQ:CCUR) is a global company that develops software solutions focused on storing, protecting, transforming, and delivering visual media assets. We serve industries and customers that demand uncompromising performance, reliability and flexibility to gain a competitive edge, drive meaningful growth and confidently deliver best-in-class solutions that enrich the lives of millions of people around the world every day.  Offices are located in North America, Europe and  Asia.  Visit www.concurrent.com for further information and follow us on Twitter: www.twitter.com/Concurrent_CCUR.

Forward Looking Statements

Certain statements in this communication and the documents referenced herein constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by words such as "anticipate," "believe," "intend," "estimate," "expect," "see," "continue," "could," "can," "may," "will," "likely," "depend," "should," "would," "plan," "predict," "target," and similar expressions, and may include references to assumptions and relate to Concurrent's future prospects, developments and business strategies. Except for the historical information contained herein, the matters discussed in this communication are forward-looking statements that involve risks and uncertainties that may cause Concurrent's actual results to be materially different from such forward-looking statements and could materially adversely affect its business, financial condition, operating results and cash flows. These risks and uncertainties include the occurrence of any event, change or other circumstances that could give rise to the termination of the Asset Purchase Agreement; or required third party consents or the failure to satisfy any of the other closing conditions to the Asset Purchase Agreement; potential disruption of management's attention from Concurrent's ongoing business operations due to the transaction; the effect of the announcement of the Asset Purchase Agreement on the ability of Concurrent to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; general business conditions; changes in overall economic conditions that impact consumer spending; the impact of competition; and other factors which are often beyond the control of Concurrent, as well other risks listed in the definitive proxy statement filed on November 6, 2017 or Concurrent's Form 10-K filed September 20, 2017 with the Securities and Exchange Commission and risks and uncertainties not presently known to Concurrent or that Concurrent currently deems immaterial. Concurrent wishes to caution you that you should not place undue reliance on such forward-looking statements, which speak only as of the date on which they were made. Concurrent does not undertake any obligation to update forward-looking statements, except as required by law.

Media Relations:
Sandra Dover
(678) 258-4112
Sandra.dover@concurrent.com

Investor Relations: 
Doug Sherk
(415) 652-9100
dsherk@evcgroup.com

Todd Kehrli
(310) 625-4462
tkehrli@evcgroup.com

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Concurrent Computer Corporation via Globenewswire

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Completion of capital reduction in Spar Nord Bank A/S26.4.2024 08:45:00 CEST | Press release

Company announcement no. 28 As stated in company announcement no. 22, it was decided at Spar Nord Bank A/S’ ordinary general meeting on 19 March 2024 to reduce the company’s share capital by DKK 27,645,950 nominal value divided into 2,764,595 shares of DKK 10 through the cancellation of treasury shares. The capital reduction was published via the Danish Business Authority’s IT system on 26 March 2024. The statutory notice period has expired with no claims received. The capital reduction has been finally registered with the Danish Business Authority on 25 April 2024. After the capital reduction, the share capital of Spar Nord Bank A/S amounts to DKK 1,177,020,310 nominal value divided into shares of DKK 10 each. Pursuant to section 32 of the Danish Capital Markets Act, we hereby announce that the company’s total share capital and total number of voting rights amount to: Share capital (nominal value): DKK 1,177,020,310 Number of voting rights: 117,702,031 Please direct any questions rega

Gennemførelse af kapitalnedsættelse i Spar Nord Bank A/S26.4.2024 08:45:00 CEST | pressemeddelelse

Selskabsmeddelelse nr. 28 Som oplyst i selskabsmeddelelse nr. 22 blev det på Spar Nord Bank A/S’ ordinære generalforsamling den 19. marts 2024 besluttet at nedsætte selskabets aktiekapital med nominelt DKK 27.645.950 fordelt i 2.764.595 aktier à DKK 10 ved annullation af egne aktier. Offentliggørelse af kapitalnedsættelsen har fundet sted i Erhvervsstyrelsens it-system den 26. marts 2024. Proklamafristen er udløbet uden indsigelser. Kapitalnedsættelsen er endeligt registreret den 25. april 2024 hos Erhvervsstyrelsen. Efter kapitalnedsættelsen udgør aktiekapitalen i Spar Nord Bank A/S nominelt DKK 1.177.020.310 fordelt i aktier à DKK 10. I henhold til §32 i lov om kapitalmarkeder oplyses det hermed, at selskabets samlede aktiekapital og samlede antal stemmerettigheder er opgjort til: Aktiekapital (nominelt): DKK 1.177.020.310 Antal stemmerettigheder: 117.702.031 Spørgsmål i forbindelse med denne meddelelse kan rettes til undertegnede på 96 34 42 36. Venlig hilsen Rune Brandt Børglum IR-

Adevinta (ASA) publishes its 2023 Annual Report26.4.2024 08:30:00 CEST | Press release

Oslo, 26 April 2024 – Adevinta ASA today released its 2023 Annual Report, available here. A printed copy may be obtained free of charge upon written request to: ir@adevinta.com. Reflecting on 2023, Antoine Jouteau, CEO, said: “Over the past year, we have made significant progress on redesigning our operating model, verticalising our organisation in line with our Growing At Scale strategy and successfully completing our portfolio optimisation. We have achieved strong financial and operational performance in 2023 and continued to deliver against our targets, despite the tough macroeconomic environment. Following the divestment of our Hungarian classifieds business, our portfolio is now centred around our core European markets of France, Germany, Spain, Italy and Benelux, complemented by Canada and our joint ventures. We are delivering significant growth in our Mobility, Re-Commerce and Real Estate & Emerging verticals, substantiating our focus in these areas. By putting technology and pr

PCI Biotech Holding ASA - Annual Report 202326.4.2024 08:08:19 CEST | Press release

Oslo, Norway, April 26, 2024. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, rs@pcibiotech.no, Mobile: +47 940 05 757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments 2023 Annual Report PCI Biotech Holding ASApcibiotechholdingasa-2023-12-31-en

Delårsrapport för januari – mars 202426.4.2024 08:00:00 CEST | Pressemelding

STOCKHOLM – den 26 april 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2024. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Det har varit en stark inledning på 2024 där utvecklingen inom respektive portföljbolag löper enligt plan. Trots att vi haft ett motigt marknadsklimat har våra portföljbolag outtröttligt fortsatt driva utvecklingen av framtidens behandlingar vidare för att de så snabbt som möjligt ska komma patienterna till gagn. Vi ser fram emot tilltagande medvind och fler framsteg under året”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget OssDsign rapporterade positiva data från den kliniska studien TOP FUSION. Top-line-resultaten, som granskats av oberoende radiologer, visar en fusionsgrad på 93 procent 12 månader efter operation med det nya nanosyntetiska bengraftet OssDsign Catalyst (januari 2024).Portföljbolaget AnaCardio erhöll SEK 50 mil

HiddenA line styled icon from Orion Icon Library.Eye